SI-BONE, Inc.

NasdaqGM SIBN

SI-BONE, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 2.88 M

SI-BONE, Inc. Net Cash Used Provided By Financing Activities is USD 2.88 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -96.83% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • SI-BONE, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 90.78 M, a 3,503.97% change year over year.
  • SI-BONE, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 2.52 M, a -96.42% change year over year.
  • SI-BONE, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 70.31 M, a 8.82% change year over year.
  • SI-BONE, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 64.61 M, a -44.66% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
NasdaqGM: SIBN

SI-BONE, Inc.

CEO Ms. Laura A. Francis MBA
IPO Date Oct. 17, 2018
Location United States
Headquarters 471 El Camino Real
Employees 344
Sector Health Care
Industries
Description

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Similar companies

OFIX

Orthofix Medical Inc.

USD 17.51

0.81%

NPCE

NeuroPace, Inc.

USD 11.84

-2.23%

SGHT

Sight Sciences, Inc.

USD 3.15

-2.78%

AXGN

AxoGen, Inc.

USD 18.24

-0.06%

CNMD

CONMED Corporation

USD 67.79

-2.46%

IRMD

IRadimed Corporation

USD 57.52

1.79%

TCMD

Tactile Systems Technology, Inc.

USD 17.46

1.51%

ESTA

Establishment Labs Holdings Inc.

USD 33.15

-1.66%

ITGR

Integer Holdings Corporation

USD 138.83

2.72%

KIDS

OrthoPediatrics Corp.

USD 23.55

-5.80%

RXST

RxSight, Inc.

USD 30.08

-2.08%

TMCI

Treace Medical Concepts, Inc.

USD 8.01

-4.19%

LUNG

Pulmonx Corporation

USD 6.84

-2.98%

StockViz Staff

January 15, 2025

Any question? Send us an email